title: The antimigraine effect of ergotamine: a role for alpha-adrenergic blockade?
abstract: The hypothesis that alpha-adrenergic receptor blockade accounts for the ability of ergotamine to stop migraine attacks was tested, in migraine patients, in an experimental migraine model based on nitroderivative- induced attacks. In a preliminary single blind, placebo controlled study, thymoxamine, a prevalently post-synaptic alpha adrenergic receptor antagonist, was able to abort migraine attack in 9 out of 10 patients, as opposed to 2 out of 10 by placebo (p < 0.005 Fisher's exact test). In a subsequent randomized, crossover, placebo controlled double blind study, the ability of a selective alpha-1 adrenergic receptor agonist, methoxamine, to block ergotamine antimigraine effect was studied. In 26 patients migraine was induced in two separate tests and then ergotamine was administered once after methoxamine pretreatment and once after placebo; methoxamine was significantly more effective than placebo in blocking antimigraine effect of ergotamine (p = 0.0055 Fisher's exact test). These results support the hypothesis that ergotamine alpha-1 adrenolytic properties may account for its antimigraine effect suggesting that this action takes place outside the blood-brain barrier, since methoxamine can cross it very poorly. Ergotamine target structure could be the trigeminal innervation of the extracranial and/or dural vessels.
authors.affiliation: Department of Neurology, School of Medicine, University Federico II of Naples, Italy.
authors.forename: S
authors.initials: S
authors.lastname: Bonuso
authors.forename: E
authors.initials: E
authors.lastname: Di Stasio
authors.forename: E
authors.initials: E
authors.lastname: Marano
authors.forename: V
authors.initials: V
authors.lastname: Covelli
authors.forename: N
authors.initials: N
authors.lastname: Testa
authors.forename: A
authors.initials: A
authors.lastname: Tetto
authors.forename: G A
authors.initials: GA
authors.lastname: Buscaino
mesh_terms: D000293:Adolescent; D000328:Adult; D003430:Cross-Sectional Studies; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D004878:Ergotamine / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008729:Methoxamine / Q000008:administration & dosage / Q000627:therapeutic use; D008881:Migraine Disorders / Q000188:drug therapy*; D013948:Moxisylyte / Q000009:adverse effects / Q000627:therapeutic use; D010919:Placebos; D011942:Receptors, Adrenergic, alpha / Q000187:drug effects*; D012965:Sodium Chloride / Q000008:administration & dosage / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D010919:Placebos; D011942:Receptors, Adrenergic, alpha; D012965:Sodium Chloride; D008729:Methoxamine; D004878:Ergotamine; D013948:Moxisylyte